Presentation
Porsolt is a pre-clinical CRO based in Laval and specialised in the assessment of the efficacy of drugs in development (pharmacology), the effect of a biological system on a drug (pharmacokinetics) and safety pharmacology (the evaluation of the adverse effects of a drug on the biological system). It is particularly active in the fields of neurology, psychology and cognition, oncology, dermatology cardiology and pain management.
*as of March 31st
Why did we invest ?
Porsolt is a leading CRO, internationally recognized for the quality and diversity of its services to pharmaceutical companies, biotechs, academic institutes and non-profit organisations.
Porsolt employs 100 people including researchers as well as highly qualified operational teams led by a committed and experienced management team.
Porsolt operates a best-in-class site in Mayenne with the capacity to support the upcoming growth phase. The company also benefits from access to a model base and scientific knowledge developed over years thanks to the stability of the teams in place as well as the certifications attesting to the exemplary nature of the company’s research procedures.
How do we intend to create value ?
Seven2’s objective is to:
– Support the management in its external growth strategy to consolidate the company’s position, particularly in the United States, and to accentuate its development in the most attractive therapeutic areas and in cutting-edge innovations.
– Reinforce the commercial strategy and increase the marketing visibility.
– Digitalise processes to optimize productivity while reinforcing the reliability of internal procedures.
Past performance is no guarantee of future performance.
The profitability of portfolio companies is never guaranteed.
